Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Shanghai, China Clinical Trials

A listing of Shanghai, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (77) clinical trials

Study of BTK Inhibitor BGB-3111 in Subjects With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma

This is an single-arm, multicenter, open-label Phase 2 study to evaluate efficacy, safety, tolerability of BGB-3111 in subjects with relapsed/refractory non-GCB type Diffuse Large B Cell Lymphoma. The study is composed of two cohorts. Cohort 1 will be approximately 70 subjects and Cohort 2 will be approximately 30 subjects.

Phase

0.0 miles

Learn More »

A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF- Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis

This is a phase , placebo-controlled, multicenter, dynamic randomized, double blind study of the efficacy and safety of RC18, a recombinant human B lymphocyte stimulating factor receptor-antibody fusion protein in subjects with inadequate response of TNF- antagonists due to treat moderate and severe rheumatoid arthritis.

Phase

0.0 miles

Learn More »

A Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic Hepatitis

Primary observation indexes: Hepatic fibrosis Ishak score after treatment decreases by the proportion not less than 1 compared with that before treatment. Secondary observation indexes : 1. Negative conversion ratio of HBV DNA after treatment (HBV DNA<1×103copies/mL) and falling range. 2. The falling proportion of Fibrocan Kpa value after treatment ...

Phase

0.0 miles

Learn More »

A Study of Mitoxantrone Hydrochloride Liposome Injection in Advanced Recurrent or Metastatic Breast Cancer

Mitoxantrone Hydrochloride Liposome Injection is a kind of anthraquinone compounds, and its antineoplastic effect has been viewed in preclinical tests. The investigator's phase study has shown that the drug's toxicity is manageable and the tolerable does is 20 mg/m2. The hypothesis of this clinical research study is to discover if ...

Phase

0.0 miles

Learn More »

Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)

To compare the effects and safety of Anlotinib with placebo in patients with esophageal squamous cell carcinoma(ESCC).

Phase

0.0 miles

Learn More »

The objective of this study is to assess efficacy and safety of radium-223 dichloride in subjects with human epidermal growth factor receptor 2 negative (HER2 negative) hormone receptor positive breast cancer with bone metastases treated with hormonal treatment background therapy.

Phase

0.0 miles

Learn More »

Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature

This was a multicenter, randomized phase II study, half of participants will receive the high dose, while the other half will receive the low dose.

Phase

0.0 miles

Learn More »

A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer

This is a Phase II, randomized, multicenter, 2-arm, open-label clinical trial designed to compare the safety and efficacy of RC48-ADC with that of capecitabine + lapatinib in participants with human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer. Participants will be treated until disease progression (PD), ...

Phase

0.0 miles

Learn More »

A Study of JS001+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment

JS001 combined with pemetrexed plus carboplatin for treatment of recurrent or advanced non-small-cell lung cancer with EGFR-mutation positive and T790M negative after progression on EGFR-TKI treatmenta multi-center, single arm phase II study

Phase

0.0 miles

Learn More »

BTK Inhibitor BGB-3111 in Chinese Patients With Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)

This is a multicenter open-label phase 2 study to evaluate efficacy, safety and tolerability of BGB-3111 160 mg twice daily in combination with rituximab in Chinese Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (non-GCB Subtype) and Relapsed/Refractory Indolent Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma. The study is composed of ...

Phase

0.0 miles

Learn More »